How VEGFR2 Antibodies Revolutionize Cancer Therapy
VEGFR2 antibodies are at the forefront of cancer therapy, offering vital innovations in combating tumor growth. Key advancements include targeting angiogenesis through VEGFR2 inhibition combined with immune checkpoint blockades, exemplified by drugs like Ramucirumab. Emerging bifunctional antibodies and strategic combination therapies promise enhanced treatment efficacy and patient survival, marking a new era in personalized oncology. […]